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The 5' adenosine monophosphate-activated protein 
kinase (AMPK) is an essential energy sensor in the cell, 
which, at low energy levels, instigates the cellular en-
ergy-generating systems along with suppression of the 
anabolic signaling pathways. The activation of AMPK 
through phosphorylation is a well-known process; 
however, activation alone is not sufficient, and 
knowledge about the other regulatory networks of 
post-translational modifications connecting the activi-
ties of AMPK to systemic metabolic syndromes is im-
portant, which is still lacking. The recent studies on 
Makorin Ring Finger Protein 1 (MKRN1) mediating the 
ubiquitination and proteasome-dependent degrada-
tion of AMPK implicate that the post-translational 
modification of AMPK, regulating its protein homeo-
stasis, could impose significant systemic metabolic 
effects (Lee et al. Nat Commun 9:3404). In this study, 
MKRN1 was identified as a novel E3 ligase for both 
AMPKα1 and α2. Mouse embryonic fibroblasts, genet-
ically deleted for Mkrmn1, and Ampkα1 and α2, be-
came stabilized with the suppression of lipogenesis 
pathways and an increase in nutrient consumption and 
mitochondria regeneration. Of note, the Mkrn1 knock-
out mice fed normal chow displayed no obvious phe-
notypic defects or abnormality, whereas the Mkrn1-
null mice exhibited strong tolerance to metabolic 
stresses induced by high-fat diet (HFD). Thus, these 
mice, when compared with the HFD-induced wild type, 
were resistant to obesity, diabetes, and non-alcoholic 
fatty liver disease. Interestingly, in whole-body Mkrn1 
knockout mouse, only the liver and white and brown 
adipose tissues displayed anincrease in the active 
phosphorylated AMPK levels, but no other organs, 
such as the hypothalamus, skeletal muscles, or pan-
creas, displayed such increases. Specific ablation of 
MKRN1 in the mouse liver using adenovirus prevented 
HFD-induced lipid accumulation in the liver and blood, 
implicating MKRN1 as a possible therapeutic target for 
metabolic syndromes, such as obesity, type II diabetes, 
and fat liver diseases. This study would provide a cru-
cial perspective on the importance of post-
translational regulation of AMPK in metabolic path-
ways and will help researchers develop novel thera-
peutic strategies that target not only AMPK but also its 
regulators. 
 
The signaling pathways instigated by the activation of 
AMP-activated protein kinase (AMPK) play major roles in 
balancing the energy levels in cells as well as in the whole-
body system by stimulating the energy expenditure. Recent 
studies have expanded the roles of AMPK in a variety of 
metabolic syndromes, such as obesity, type 2 diabetes, 
fatty liver syndrome, cardiovascular diseases, and tumor-
igenesis. In particular, its effects on the formation of brown 
and beige adipose tissues and regeneration of mitochon-
dria make AMPK an attractive target to control or cure 
metabolic diseases. As a cellular energy-sensing enzyme, 
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prised of a catalytic (α1 or α2) subunit and two regulatory 
subunits (β1 or β2 and γ1, γ2 or γ3). Under the energy 
stress condition of higher AMP/ATP ratio, AMP binds to γ 
subunits, allosterically activating AMPK, leading to an in-
duction of catabolism with concomitant suppression of 
anabolism. While the phosphorylation of AMPK has been 
unveiled to be mediated by kinases such as liver kinase B1 
(LKB1) and  calcium  calmodulin-dependent  protein  kinase  
kinase β (CAMKKβ), regulation of AMPK by other post-
translational modifications, such as ubiquitination, still 
need to be elucidated. This regulatory mechanism is neces-
sary to understand the relevant physiological effects of 
AMPK, including metabolic syndromes. In the recent stud-
ies of E3 ligase, MKRN1, and AMPKα, it has been shown 
that the suppression of AMPKα activities by MKRN1 could 
have metabolically systemic effects. Of note, while MKRN1 
is expressed in most of the organs, the Mkrn1 knockout 
mouse shows an increase of levels of AMPK and its activi-
ties only in the liver and adipose tissues, the two major 
metabolic organs. Accordingly, lipid accumulation in this 
knockout mouse was prevented as expected for mice with 
higher AMPK levels. This leads to the prevention of diseas-
es related to metabolic syndromes, such as lowerblood 
lipid and cholesterol levels, insulin intolerance, type II dia-
betes, and steatosis. Since MKRN1 is generally expressed in 
most organs, it is of interest to identify a factor that might 
suppress MRKN1 and AMPKα interaction in organs other 
than the liver and adipose tissues. The effects of Mkrn1 
knockout on AMPK activation in vivo in the presence of 
HFD were comprehensively interpreted by cellular path-
FIGURE 1: Regulation of Metabolism in MKRN1 knockout mice. Network models describing alterations of cellular processes regulated by 
DEGs in MKRN1-null liver and adipose tissue. Solid lines denote metabolic reactions and dotted lines denote transports of molecules or 
transcriptional regulations between transcriptional regulators and their target genes. Node center and border colors represent up- (red) or 
down-regulation (green) in MKRN1-null liver (center) and adipose tissue (border; see the legend for node center and border). The color bar 
represents the gradient of log2-fold-changes of mRNA expression levels by MKRN1 ablation relative to those in WT. Plasma membranes 
were denoted by thick gray lines, cytoplasm by blue background, and extracellular matrix by white background. 
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ways represented by the differentially expressed genes 
(DEGs) between Mkrn1 knockout and wild type mice in the 
liver and adipose tissues. In Figure 1, the effects of Mkrn1 
depletion on AMPK activation in the mouse liver and adi-
pose tissues are presented based on the pathways sup-
pressed or activated. These analyses showed that the 
pathways associated with lipid consumption or accumula-
tion were the most affected by Mkrn1 knockout. As ex-
pected, enzymes such as ACACA/B, FASN, TECR, HSD17B12, 
ELOVL1/2/5/6/7, SCD1/2, and ACOT, which are related to 
lipid anabolism starting from acetyl-CoA, were considera-
bly suppressed upon Mkrn1 depletion. On the other hand, 
the pathways involved in lipolysis were up-regulated, cor-
roborating the effect of active AMPK. Notably, the genes 
including Pgc1, Cidea, Prdm16, and Ucp1, which are in-
volved in the differentiation and function of brown adipo-
cytes, were up-regulated. Although we did not pursue the 
differentiation of brown or beige adipocytes under various  
environmental conditions in this study, the up-regulation 
of these genes warrants further investigations to elucidate 
the possible association of Mkrn1 depletion in facilitating 
the browning or beiging process of adipocytes. In the 
Mkrn1 knockout mice, glucose uptake and consumption 
were generally up-regulated in the adipose tissues, while 
gluconeogenesis was down-regulated in the liver, which 
corroborates the diabetes-free condition in Mkrn1 knock-
out mice fed HFD. Interestingly, in Mkrn1 knockout mice, 
the upstream and downstream pathways of mTOR were 
globally suppressed in the liver. For example, the AKT 
pathway was down-regulated compared to that in the wild 
type mice fed HFD. In corroboration with these data, the 
downstream targets of mTOR were also inhibited, indicat-
ing that activation of AMPK upon suppression of MKRN1 
would negatively regulate the mTOR pathway. The extent 
of inhibition of mTOR upon Mkrn1 knockout, however, 
might involve other factors regulated by MKRN1. 
While the influence of MKRN1 on AMPK seems to have 
a very potent effect on the regulation of metabolic path-
ways, the other signaling pathways regulated by MKRN1 
could not be ignored. MKRN1 is an E3 ligase engaged in 
various signaling pathways. In particular, it is known to 
target potent tumor suppressors closely associated with 
FIGURE 2: Targets of MKRN1. MKRN1 mediates the ubiquitination of AMPKα, p14ARF, p53, FADD, PTEN, and APC, which are then de-
graded via the proteasome-dependent pathway. AMPK, the energy sensor inducing catabolism, is also an activator of p53, which in turn 
enforces the function of PTEN, APC, and FADD via direct or indirect regulation. In particular, induction of PTEN by p53 leads to the sup-
pression of AKT and thus of mTOR pathways, inhibiting the anabolic pathways. Thus, MKRN1 might have comprehensive effects on gen-
eral metabolic pathways by regulating the factors involved. 
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p53. MKRN1 degrades p14ARF, which is induced by an on-
cogene, such as c-Myc, and also is a negative regulator of 
MDM2, an obligatory E3 ligase of p53 (Figure 2). Thus, on-
cogenic signaling instigates the senescence process by acti-
vating p14ARF and subsequently p53 as a way to prevent 
cells from becoming tumorigenic. The tumor-suppressor 
protein p53 is also a transcriptional activator of PTEN, a 
phosphatase that dephosphorylates phosphatidylinositol-
3,4,5-trisphosphate to phosphatidylinositol-4,5-
trisphosphate. This process suppresses the downstream 
signaling of phosphatidylinositide 3 (PI3)-kinase, which 
leads to the inactivation of AKT and subsequently mTOR, 
which is the master regulator of anabolic pathways. Thus, 
activation of p53 could result in cellular senescence with 
suppression of anabolic processes, a typical signature pre-
venting an oncogenic process. Of note, MKRN1 could in-
duce the degradation of p14ARF, p53, and PTEN, which 
could lead to the rearrangement of metabolic homeostasis 
causing possible induction or suppression of anabolism or 
catabolism, respectively. In addition to this plausible ten-
dency of MKRN1 to promote anabolism, MKRN1 is also 
capable to induce the ubiquitination and proteasome-
dependent degradation of AMPK, which would potentiate 
these processes. It would be interesting to further investi-
gate the effects of MKRN1-mediated AMPK suppression on 
p53 and mTOR, the targets of AMPK. Based on these ob-
servations, MKRN1 could be considered as a regulatory 
factor that inhibits the cellular energy consumption pro-
cess, thus prompting the accumulation of metabolic mac-
romolecules. Besides these functions, MKRN1 also acts as a 
negative regulator of FADD (Fas-associated death domain) 
and APC (Adenomatous polyposis coli) proteins, which are 
essential factors in cytokine-dependent cell death and Wnt 
signaling. An association of these pathways with the meta-
bolic processes, involving the AMPK pathway regulated by 
MKRN1, could not be excluded as a plausible crosstalk.  
In summary, MKRN1 functions as an E3 ubiquitin ligase 
prompting AMPKα destabilization, specifically in the liver 
and white and brown adipose tissues. AMPK activation 
under depletion of Mkrn1 in mice accelerated the con-
sumption of nutrients, including lipids, in these tissues, 
facilitating more energy expenditure and preventing meta-
bolic syndromes, such as the liver steatosis, insulin re-
sistance, and obesity induced by HFD. The therapeutic po-
tential of MKRN1 inhibition in hyperglycemia and hepatic 
steatosis was revealed using adenoviral gene specifically 
delivered to the liver. Further studies using a conditional 
Mkrn1 knockout mouse are required to investigate the 
protein’s therapeutic effects on serious metabolic diseases, 
such as nonalcoholic steatohepatitis.  
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